Curium is the world’s largest nuclear medicine company following the union of two  major North American and European suppliers. We develop, manufacture and distribute  world-class radiopharmaceutical products to help patients around the globe. Our proven  heritage combined with a pioneering approach are the hallmarks to deliver innovation,  excellence and unparalleled service. The name ‘Curium’ honors the legacy of pioneering radioactive researchers Marie and Pierre Curie,  after whom the radioactive element curium was named. The tagline ‘Life Forward’ represents our commitment to securing a brighter future for all those we serve: An enhanced quality of care for our patients. A trusted partner to our customers. A supportive employer to our valued team. Since our formation in 2017, we are pleased to report solid financial performance, which in turn supports significant investments to accelerate our growth through new product development and acquisitions. By reinvesting back into our business and products, we remain firmly focused on delivering vital products to over 35,000 patients who are in need of crucial diagnosis and treatment every day. In 2018, Curium became the first to offer 100% LEU generators in North America and has since expanded to supply LEU generators globally. We recently secured a contract supporting Curium’s long term molybdenum production. Through acquisition, we expanded our Positron Emission Tomography (PET) network to 26 sites world-wide, executed agreements for the development and distribution of new PET diagnostic agents and added new products to our portfolio. Another key achievement was our CEO, Renaud Dehareng, receiving prestigious recognition as one of USA’s top CEOs in 2017 and winning CEO Healthcare Award in 2018.

Women with her child both wearing masks in a cancer ward looking at a picture board, with the child pointing at a picture of three doctors

There is much that governments, organisations and individuals can do to reduce inequity and ensure that affordable, quality care is enjoyed by all populations.

Young boy sitting on a pile of tobacco leaves

N°1 dermatologist recommended skincare brand worldwide, La Roche-Posay’s mission is to offer life-changing dermatological skincare solutions. Recommended by 90,000 dermatologists worldwide*, La Roche-Posay was created by a pharmacist in 1975. The brand is today present in over 60 countries. It offers a unique range of daily skincare developed for every skin type to complement their dermatological treatments and promote good skincare practices adapted to each skin concern. The brand develops formulas with its exclusive Selenium-rich water, also used at its Thermal Center, the first Dermatology Center in Europe, due to its antioxidant and soothing properties. The products are developed using a strict formulation charter with a minimal number of ingredients and are formulated at optimal concentrations. Additionally, La Roche-Posay products undergo stringent clinical testing for efficacy and safety, even on sensitive skin.  The La Roche-Posay Cancer Support program includes two pillars related to the fight against cancer: Fight With Care to improve patients’ quality of life during all cancer treatment for better adherence and higher chances of healing, and Save Your Skin to prevent skin cancer specifically. On both topics, the brand is committed to raising awareness, training health care professional and the general public, and helping patients by supporting NGOs’ projects beyond skincare. Since 2019, the Fondation La Roche-Posay is also committed to improving the life of children with cancer and their families. In 2020, the brand went a step further in its commitment to protect the planet. Besides launching the first eco-designed tubes integrating cardboard, the brand announced a long-term plan to reduce its use of virgin plastic by 70% in 2025.

For additional information about La Roche-Posay, visit www.laroche-posay.com.

*source: survey on the dermocosmetic market carried out by iqvia and other partners (ipsos, tns) between september 2017 and august 2018 among dermatologists in 62 countries.

Two people attending a UICC event greeting one another.

The overwhelming positive feedback from the recent UICC member survey provides insight into how UICC can develop its services in the future.

Chemotherapy treatment at the Aga Khan University Hospital in Nairobi, Kenya. (c) Union for Internationa Cancer Control (UICC)

The Access to Oncology Medicines (ATOM) Coalition is an innovative collaboration model that will increase access to cancer medicines in LLMICs in a novel and sustainable way.

Logs piled outside tobacco curing barns in Malawi.

Marking the upcoming World No Tobacco Day, Sonja von Eichborn explores the tobacco industry’s toll on the environment and its greenwashing strategy.

Subscribe to